Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Passage Bio announces new CCO, CFO, CMO appointments » 07:05
07/19/21
07/19
07:05
07/19/21
07:05
PASG

Passage Bio

$12.30 /

+0.56 (+4.77%)

, SRPT

Sarepta

$67.03 /

-1.36 (-1.99%)

Passage Bio (PASG)…

Passage Bio (PASG) announced three key leadership appointments. These executives will support the company's growth and further enhance the company's strong clinical development capabilities in managing its robust pipeline. Maria Tornsen joins Passage Bio as chief commercial officer, or CCO, effective today. She reports to Passage Bio President and Chief Executive Officer Bruce Goldsmith, Ph.D., and is a member of the executive team. She is responsible for leading and building out the company's commercial organization and strategy, including determining product positioning and paths to commercialization. Prior to joining Passage Bio, Tornsen, who has nearly 20 years of global commercial experience, was at Sarepta Therapeutics (SRPT), where she was senior vice president, general manager, U.S. Simona King will join Passage Bio as chief financial officer, or CFO, effective August 23 She will report to Goldsmith and will be a member of the executive team. She will be responsible for finance, accounting, tax, treasury, investor relations functions and information technology. King, the former executive vice president and CFO at Tmunity Therapeutics, has more than 20 years of pharmaceutical and biotech strategic finance experience. Mark Forman, M.D., Ph.D., will join Passage Bio as chief medical officer, or CMO, effective July 30. He will report to the Chief Research & Development Officer Eliseo Salinas, M.D., MSc., and will be responsible for leading the company's translational and clinical development efforts. Forman has nearly two decades of experience in translational research for neurological disorders, having served as head of translational medicine at Acadia and translational research for neuroscience at Merck. He will join Passage Bio from the Alzheimer's Drug Discovery Foundation, where he oversaw the drug discovery and development portfolio.

ShowHide Related Items >><<
SRPT Sarepta
$67.03 /

-1.36 (-1.99%)

PASG Passage Bio
$12.30 /

+0.56 (+4.77%)

PASG Passage Bio
$12.30 /

+0.56 (+4.77%)

07/09/21 Chardan
Passage Bio coverage transferred at Chardan
07/01/21 Raymond James
Passage Bio initiated with an Outperform at Raymond James
06/30/21 Raymond James
Passage Bio initiated with an Outperform at Raymond James
06/14/21 BTIG
Passage Bio initiated with a Buy at BTIG
SRPT Sarepta
$67.03 /

-1.36 (-1.99%)

07/01/21 Berenberg
Sarepta assumed with a Hold at Berenberg
06/14/21 BTIG
Sarepta initiated with a Buy at BTIG
05/18/21 William Blair
William Blair says continued lack of '9001 safety signals positive for Sarepta
05/03/21 William Blair
Sarepta data confirm potential of PPMO platform, says William Blair
SRPT Sarepta
$67.03 /

-1.36 (-1.99%)

PASG Passage Bio
$12.30 /

+0.56 (+4.77%)

  • 22
    Jan
SRPT Sarepta
$67.03 /

-1.36 (-1.99%)

PASG Passage Bio
$12.30 /

+0.56 (+4.77%)

Conference/Events
Piper Sandler biotech analysts hold an analyst/industry conference call » 14:55
07/15/21
07/15
14:55
07/15/21
14:55
LOGC

LogicBio Therapeutics

$3.76 /

-0.15 (-3.84%)

, SRPT

Sarepta

$67.86 /

+1.03 (+1.54%)

, NTLA

Intellia Therapeutics

$135.19 /

-5.81 (-4.12%)

, VERV

Verve Therapeutics

$47.67 /

-1.86 (-3.76%)

Biotech Analyst Rahimi,…

Biotech Analyst Rahimi, along with Mark A. Kay, MD, PhD, discuss Cardiovascular Gene Therapy on an Analyst/Industry conference call to be held on July 15 at 3 pm. Webcast Link

ShowHide Related Items >><<
VERV Verve Therapeutics
$47.67 /

-1.86 (-3.76%)

SRPT Sarepta
$67.86 /

+1.03 (+1.54%)

NTLA Intellia Therapeutics
$135.19 /

-5.81 (-4.12%)

LOGC LogicBio Therapeutics
$3.76 /

-0.15 (-3.84%)

LOGC LogicBio Therapeutics
$3.76 /

-0.15 (-3.84%)

06/07/21
Fly Intel: Top five analyst initiations
06/07/21 H.C. Wainwright
LogicBio Therapeutics initiated with a Buy at H.C. Wainwright
04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
03/04/21 JMP Securities
LogicBio Therapeutics initiated with an Outperform at JMP Securities
SRPT Sarepta
$67.86 /

+1.03 (+1.54%)

07/01/21 Berenberg
Sarepta assumed with a Hold at Berenberg
06/14/21 BTIG
Sarepta initiated with a Buy at BTIG
05/18/21 William Blair
William Blair says continued lack of '9001 safety signals positive for Sarepta
05/03/21 William Blair
Sarepta data confirm potential of PPMO platform, says William Blair
NTLA Intellia Therapeutics
$135.19 /

-5.81 (-4.12%)

06/30/21 Piper Sandler
Poseida Therapeutics being overlooked after Intellia data, says Piper Sandler
06/29/21 Cowen
Alnylam weakness a buying opportunity, says Cowen
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
06/29/21 Oppenheimer
Intellia Therapeutics price target raised to $125 from $73 at Oppenheimer
VERV Verve Therapeutics
$47.67 /

-1.86 (-3.76%)

07/12/21 JPMorgan
Verve Therapeutics initiated with a Neutral at JPMorgan
07/12/21 Jefferies
Verve Therapeutics initiated with a Buy at Jefferies
07/12/21 Guggenheim
Verve Therapeutics initiated with a Buy at Guggenheim
07/12/21 William Blair
Verve Therapeutics initiated with an Outperform at William Blair
SRPT Sarepta
$67.86 /

+1.03 (+1.54%)

NTLA Intellia Therapeutics
$135.19 /

-5.81 (-4.12%)

LOGC LogicBio Therapeutics
$3.76 /

-0.15 (-3.84%)

  • 30
    Jun
  • 17
    Jun
  • 02
    Dec
  • 01
    Oct
VERV Verve Therapeutics
$47.67 /

-1.86 (-3.76%)

SRPT Sarepta
$67.86 /

+1.03 (+1.54%)

NTLA Intellia Therapeutics
$135.19 /

-5.81 (-4.12%)

LOGC LogicBio Therapeutics
$3.76 /

-0.15 (-3.84%)

Conference/Events
Piper Sandler biotech analysts hold an analyst/industry conference call » 10:36
07/15/21
07/15
10:36
07/15/21
10:36
LOGC

LogicBio Therapeutics

$3.91 /

+ (+0.00%)

, SRPT

Sarepta

$67.30 /

+0.47 (+0.70%)

, NTLA

Intellia Therapeutics

$140.18 /

-0.82 (-0.58%)

, VERV

Verve Therapeutics

$49.02 /

-0.51 (-1.03%)

Biotech Analyst Rahimi,…

Biotech Analyst Rahimi, along with Mark A. Kay, MD, PhD, discuss Cardiovascular Gene Therapy on an Analyst/Industry conference call to be held on July 15 at 3 pm. Webcast Link

ShowHide Related Items >><<
VERV Verve Therapeutics
$49.02 /

-0.51 (-1.03%)

SRPT Sarepta
$67.30 /

+0.47 (+0.70%)

NTLA Intellia Therapeutics
$140.18 /

-0.82 (-0.58%)

LOGC LogicBio Therapeutics
$3.91 /

+ (+0.00%)

LOGC LogicBio Therapeutics
$3.91 /

+ (+0.00%)

06/07/21
Fly Intel: Top five analyst initiations
06/07/21 H.C. Wainwright
LogicBio Therapeutics initiated with a Buy at H.C. Wainwright
04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
03/04/21 JMP Securities
LogicBio Therapeutics initiated with an Outperform at JMP Securities
SRPT Sarepta
$67.30 /

+0.47 (+0.70%)

07/01/21 Berenberg
Sarepta assumed with a Hold at Berenberg
06/14/21 BTIG
Sarepta initiated with a Buy at BTIG
05/18/21 William Blair
William Blair says continued lack of '9001 safety signals positive for Sarepta
05/03/21 William Blair
Sarepta data confirm potential of PPMO platform, says William Blair
NTLA Intellia Therapeutics
$140.18 /

-0.82 (-0.58%)

06/30/21 Piper Sandler
Poseida Therapeutics being overlooked after Intellia data, says Piper Sandler
06/29/21 Cowen
Alnylam weakness a buying opportunity, says Cowen
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
06/29/21 Oppenheimer
Intellia Therapeutics price target raised to $125 from $73 at Oppenheimer
VERV Verve Therapeutics
$49.02 /

-0.51 (-1.03%)

07/12/21 JPMorgan
Verve Therapeutics initiated with a Neutral at JPMorgan
07/12/21 Jefferies
Verve Therapeutics initiated with a Buy at Jefferies
07/12/21 Guggenheim
Verve Therapeutics initiated with a Buy at Guggenheim
07/12/21 William Blair
Verve Therapeutics initiated with an Outperform at William Blair
SRPT Sarepta
$67.30 /

+0.47 (+0.70%)

NTLA Intellia Therapeutics
$140.18 /

-0.82 (-0.58%)

LOGC LogicBio Therapeutics
$3.91 /

+ (+0.00%)

  • 30
    Jun
  • 17
    Jun
  • 02
    Dec
  • 01
    Oct
VERV Verve Therapeutics
$49.02 /

-0.51 (-1.03%)

SRPT Sarepta
$67.30 /

+0.47 (+0.70%)

NTLA Intellia Therapeutics
$140.18 /

-0.82 (-0.58%)

LOGC LogicBio Therapeutics
$3.91 /

+ (+0.00%)

Over a month ago
Initiation
Sarepta assumed with a Hold at Berenberg » 10:18
07/01/21
07/01
10:18
07/01/21
10:18
SRPT

Sarepta

$77.78 /

+0.03 (+0.04%)

Berenberg analyst…

Berenberg analyst Zhiqiang Shu assumed coverage of Sarepta with a Hold rating and $85 price target. While there is considerable uncertainty around Sarepta's Phase 3 DMD trial and the potential regulatory pathway, Shu believes the company's three approved DMD drugs provide valuation support, at least for now, the analyst tells investors in a research note.

ShowHide Related Items >><<
SRPT Sarepta
$77.78 /

+0.03 (+0.04%)

SRPT Sarepta
$77.78 /

+0.03 (+0.04%)

06/14/21 BTIG
Sarepta initiated with a Buy at BTIG
05/18/21 William Blair
William Blair says continued lack of '9001 safety signals positive for Sarepta
05/03/21 William Blair
Sarepta data confirm potential of PPMO platform, says William Blair
05/03/21 Needham
Needham says Sarepta's SRP-5051 has potential of improving on approved DMD drugs
SRPT Sarepta
$77.78 /

+0.03 (+0.04%)

SRPT Sarepta
$77.78 /

+0.03 (+0.04%)

Initiation
Sarepta initiated with a Buy at BTIG » 16:39
06/14/21
06/14
16:39
06/14/21
16:39
SRPT

Sarepta

$85.95 /

-0.03 (-0.03%)

BTIG analyst Yun Zhong…

BTIG analyst Yun Zhong initiated coverage of Sarepta with a Buy rating and $110 price target. The analyst remains optimistic on the ultimate FDA approval for SRP-9001 and believes that the program deserves higher valuation than what is reflected in the current share price.

ShowHide Related Items >><<
SRPT Sarepta
$85.95 /

-0.03 (-0.03%)

SRPT Sarepta
$85.95 /

-0.03 (-0.03%)

05/18/21 William Blair
William Blair says continued lack of '9001 safety signals positive for Sarepta
05/03/21 William Blair
Sarepta data confirm potential of PPMO platform, says William Blair
05/03/21 Needham
Needham says Sarepta's SRP-5051 has potential of improving on approved DMD drugs
04/26/21 Credit Suisse
Sarepta assumed with a Neutral at Credit Suisse
SRPT Sarepta
$85.95 /

-0.03 (-0.03%)

SRPT Sarepta
$85.95 /

-0.03 (-0.03%)

Recommendations
William Blair says continued lack of '9001 safety signals positive for Sarepta » 12:48
05/18/21
05/18
12:48
05/18/21
12:48
SRPT

Sarepta

$83.75 /

+8.805 (+11.75%)

, SLDB

Solid Biosciences

$3.86 /

+0.31 (+8.73%)

, PFE

Pfizer

$40.08 /

-0.035 (-0.09%)

William Blair analyst Tim…

William Blair analyst Tim Lugo noted that Sarepta Therapeutics (SRPT) presented 12-week expression and safety results from Part 1 for the first 11 patients from Study 103 evaluating the commercially representative material for gene therapy candidate SRP-9001 for the treatment of Duchenne muscular dystrophy, or DMD, before today's open. On the safety side, Sarepta's continued lack of safety signals is "a strong positive" given that safety concerns have led to the halting of trials for competing DMD gene therapies such as Solid Biosciences' (SLDB) SGT-001 and Pfizer's (PFE) PF-06939926, Lugo tells investors. Lugo, who thinks results from Study 103 showing "strong and consistent microdystrophin expression levels across subjects" continue to support the company's decision to advance the program, has an Outperform rating on Sarepta shares.

ShowHide Related Items >><<
SRPT Sarepta
$83.75 /

+8.805 (+11.75%)

SLDB Solid Biosciences
$3.86 /

+0.31 (+8.73%)

PFE Pfizer
$40.08 /

-0.035 (-0.09%)

SRPT Sarepta
$83.75 /

+8.805 (+11.75%)

05/03/21 William Blair
Sarepta data confirm potential of PPMO platform, says William Blair
05/03/21 Needham
Needham says Sarepta's SRP-5051 has potential of improving on approved DMD drugs
04/26/21 Credit Suisse
Sarepta assumed with a Neutral at Credit Suisse
03/02/21 RBC Capital
Sarepta price target lowered to $132 from $143 at RBC Capital
SLDB Solid Biosciences
$3.86 /

+0.31 (+8.73%)

05/17/21 Barclays
Solid Biosciences price target lowered to $8 from $13 at Barclays
03/16/21 Chardan
Solid Biosciences price target raised to $20 from $12.50 at Chardan
03/16/21
Fly Intel: Top five analyst upgrades
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform at SVB Leerink
PFE Pfizer
$40.08 /

-0.035 (-0.09%)

05/12/21 Canaccord
BioNTech price target raised to $240 from $130 at Canaccord
05/11/21 SVB Leerink
BioNTech price target raised to $159 from $118 at SVB Leerink
05/10/21 Morgan Stanley
Pfizer price target raised to $42 from $38 at Morgan Stanley
05/06/21
Fly Intel: Top five analyst downgrades
SRPT Sarepta
$83.75 /

+8.805 (+11.75%)

SLDB Solid Biosciences
$3.86 /

+0.31 (+8.73%)

PFE Pfizer
$40.08 /

-0.035 (-0.09%)

  • 19
    Mar
PFE Pfizer
$40.08 /

-0.035 (-0.09%)

SRPT Sarepta
$83.75 /

+8.805 (+11.75%)

SLDB Solid Biosciences
$3.86 /

+0.31 (+8.73%)

PFE Pfizer
$40.08 /

-0.035 (-0.09%)

PFE Pfizer
$40.08 /

-0.035 (-0.09%)

Hot Stocks
Sarepta announces 12-week expression, safety results from study of SRP-9001 » 08:58
05/18/21
05/18
08:58
05/18/21
08:58
SRPT

Sarepta

$75.06 /

-0.87 (-1.15%)

, RHHBY

Roche

$42.20 /

+0.07 (+0.17%)

Sarepta Therapeutics…

Sarepta Therapeutics announced positive 12-week expression and safety results from the first 11 participants enrolled in Study SRP-9001-103, an open-label study known as ENDEAVOR being conducted in partnership with Roche. In results from the first clinical study using commercially representative material, SRP-9001 demonstrated robust expression of micro-dystrophin and no new safety signals from prior studies, supporting its potentially differentiated profile for the treatment of Duchenne muscular dystrophy. SRP-9001 is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein. In the open-label study, 20 participants between the ages of four and seven were treated with a single infusion of SRP-9001 at a dose of 1.33x1014 vg/kg. In muscle biopsies from the first 11 patients taken 12 weeks after treatment, the following results were observed: All patients demonstrated robust transduction, with mean micro-dystrophin expression of 55.4% of normal, as measured by western blot. Muscle dystrophin levels demonstrated a mean of 70.5% muscle fibers expressing micro-dystrophin at 12 weeks with a mean intensity at the sarcolemma of 116.9% compared to normal biopsies, as measured by immunofluorescence. Comparisons between baseline and post-treatment measures were statistically significant. Mean vector genome copies per nucleus reached 3.87. The safety profile of SRP-9001 observed in the first 11 participants in ENDEAVOR is consistent with the safety seen in earlier studies using clinical manufacturing process material. In line with previously reported clinical data, no clinically relevant complement activation was observed in these 11 patients. Two patients experienced serious adverse events that fully resolved.

ShowHide Related Items >><<
SRPT Sarepta
$75.06 /

-0.87 (-1.15%)

RHHBY Roche
$42.20 /

+0.07 (+0.17%)

SRPT Sarepta
$75.06 /

-0.87 (-1.15%)

05/03/21 William Blair
Sarepta data confirm potential of PPMO platform, says William Blair
05/03/21 Needham
Needham says Sarepta's SRP-5051 has potential of improving on approved DMD drugs
04/26/21 Credit Suisse
Sarepta assumed with a Neutral at Credit Suisse
03/02/21 RBC Capital
Sarepta price target lowered to $132 from $143 at RBC Capital
RHHBY Roche
$42.20 /

+0.07 (+0.17%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
SRPT Sarepta
$75.06 /

-0.87 (-1.15%)

RHHBY Roche
$42.20 /

+0.07 (+0.17%)

RHHBY Roche
$42.20 /

+0.07 (+0.17%)

SRPT Sarepta
$75.06 /

-0.87 (-1.15%)

RHHBY Roche
$42.20 /

+0.07 (+0.17%)

Earnings
Sarepta reports Q1 EPS ($2.10), consensus ($1.77) » 16:53
05/05/21
05/05
16:53
05/05/21
16:53
SRPT

Sarepta

$72.75 /

-1.26 (-1.70%)

Reports Q1 revenue…

Reports Q1 revenue $146.93M, consensus $143.33M. "In the first quarter, we obtained FDA approval for and launched our third RNA therapy for Duchenne, AMONDYS 45(TM) (casimersen). The first AMONDYS 45 patient was treated within the first week of approval. Serving the community with EXONDYS 51, VYONDYS 53, and AMONDYS 45, we achieved net product revenue of $124.9 million, a 24% increase over the same quarter in 2020," stated Doug Ingram, Sarepta's president and CEO. "We also made significant strides in the advancement of our pipeline. Two days ago we announced positive results for the 30 mg/kg cohort of SRP-5051, our lead PPMO candidate. As we reported, after a median of only 12-weeks and three doses, the PPMO showed a significant dose-dependent increase in expression, exhibiting an 18 times greater level of exon skipping and nearly an order of magnitude greater level of dystrophin production as compared to EXONDYS 51, the currently approved standard of care for those with Duchenne amenable to exon 51 skipping. SRP-5051 achieved this in about half the time as EXONDYS 51 and with only about 12% of the dose exposure."

ShowHide Related Items >><<
SRPT Sarepta
$72.75 /

-1.26 (-1.70%)

SRPT Sarepta
$72.75 /

-1.26 (-1.70%)

05/03/21 William Blair
Sarepta data confirm potential of PPMO platform, says William Blair
05/03/21 Needham
Needham says Sarepta's SRP-5051 has potential of improving on approved DMD drugs
04/26/21 Credit Suisse
Sarepta assumed with a Neutral at Credit Suisse
03/02/21 RBC Capital
Sarepta price target lowered to $132 from $143 at RBC Capital
SRPT Sarepta
$72.75 /

-1.26 (-1.70%)

SRPT Sarepta
$72.75 /

-1.26 (-1.70%)

Recommendations
Sarepta data confirm potential of PPMO platform, says William Blair » 12:40
05/03/21
05/03
12:40
05/03/21
12:40
SRPT

Sarepta

$75.80 /

+4.94 (+6.97%)

William Blair analyst Tim…

William Blair analyst Tim Lugo keeps an Outperform rating on Sarepta Therapeutics announced results from the 30 mg/kg arm of the multi-ascending dose study of SRP-5051 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping. At 12 weeks, SRP-5051 resulted in dose-dependent increases in exon skipping compared to baseline, says the analyst. While Lugo cautions against comparisons with different trials with a small number of patients, he notes that the 30 mg/kg dose achieved a four-times greater increase in exon skipping compared to the 20 mg/kg dose of SRP-5051, and an 18-times greater increase in exon skipping compared to the 30 mg/kg eteplirsen at 24 weeks observed in the PROMOVI trial. Lugo views the data as confirming the potential of Sarepta's phosphorodiamidate morpholino oligomer technology program.

ShowHide Related Items >><<
SRPT Sarepta
$75.80 /

+4.94 (+6.97%)

SRPT Sarepta
$75.80 /

+4.94 (+6.97%)

05/03/21 Needham
Needham says Sarepta's SRP-5051 has potential of improving on approved DMD drugs
04/26/21 Credit Suisse
Sarepta assumed with a Neutral at Credit Suisse
03/02/21 RBC Capital
Sarepta price target lowered to $132 from $143 at RBC Capital
03/02/21 Piper Sandler
Sarepta price target lowered to $130 from $140 at Piper Sandler
SRPT Sarepta
$75.80 /

+4.94 (+6.97%)

SRPT Sarepta
$75.80 /

+4.94 (+6.97%)

Recommendations
Needham says Sarepta's SRP-5051 has potential of improving on approved DMD drugs » 11:15
05/03/21
05/03
11:15
05/03/21
11:15
SRPT

Sarepta

$74.50 /

+3.64 (+5.14%)

After Sarepta reported…

After Sarepta reported updated results from its multi-dose ascending study of SRP-5051 in Duchenne Muscular Dystrophy, or DMD, patients, Needham analyst Chad Messer noted that the observed activity in both exon skipping and subsequent dystrophin expression were "materially higher" with the 30 mg/kg dose than those seen at the 20 mg/kg dose or with approved Exondys. The analyst, who notes that Sarepta plans on initiating regulatory discussions on accelerated approval for SRP-5051 and using 30 mg/kg as the go-forward dose, believes that SRP-5051 has the potential of improving on commercial drugs Exondys, Vyondys and Amondys with lower monthly dosing and higher target expression. Messer has a Buy rating and $166 price target on Sarepta shares.

ShowHide Related Items >><<
SRPT Sarepta
$74.50 /

+3.64 (+5.14%)

SRPT Sarepta
$74.50 /

+3.64 (+5.14%)

04/26/21 Credit Suisse
Sarepta assumed with a Neutral at Credit Suisse
03/02/21 RBC Capital
Sarepta price target lowered to $132 from $143 at RBC Capital
03/02/21 Piper Sandler
Sarepta price target lowered to $130 from $140 at Piper Sandler
02/26/21 Mizuho
Sarepta price target raised to $160 from $158 at Mizuho
SRPT Sarepta
$74.50 /

+3.64 (+5.14%)

SRPT Sarepta
$74.50 /

+3.64 (+5.14%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.